Monday, August 01, 2022 8:01:15 AM
7:52 pm ET July 27, 2022 (BusinessWire) Print
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company's common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less discounts and commissions, to cover over-allotments.
The shares of common stock are expected to begin trading on the NYSE American under the ticker symbol "MAIA" on July 28, 2022. The offering is expected to close on August 1, 2022, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the initial public offering to fund the first part of the Phase 2 trials of the Company's product candidate THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities, as well as for working capital and other general corporate purposes.
ThinkEquity is acting as sole book-running manager for the offering.
The registration statement on Form S-1 (file No. 333-264225) relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and became effective on July 27, 2022. A final prospectus related to the proposed offering will be filed and made available on the SEC's website at https://www.sec.gov/. The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 and by email at prospectus@think-equity.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006179/en/
SOURCE: MAIA Biotechnology, Inc.
Investor Inquiries
ICR Westwicke
Stephanie Carrington
Stephanie.carrington@westwicke.com
646-277-1282
New York Yankees and Duke Basketball
Recent MAIA News
- MAIA Biotechnology to Present at the BIO International Convention 2024 • Business Wire • 05/17/2024 12:37:00 PM
- MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting • Business Wire • 05/16/2024 12:37:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/15/2024 08:05:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:11:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:21:03 PM
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement • Business Wire • 04/30/2024 12:08:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement • Business Wire • 04/29/2024 12:08:00 PM
- MAIA Biotechnology Announces $1.00 Million Private Placement • Business Wire • 04/23/2024 12:51:00 PM
- MAIA Biotechnology to Present at Two Investor Conferences in April 2024 • Business Wire • 04/05/2024 12:01:00 PM
- MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero • Business Wire • 03/28/2024 07:00:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement • Business Wire • 03/26/2024 07:00:00 PM
- MAIA Biotechnology Announces $1.33 Million Private Placement • Business Wire • 03/26/2024 12:01:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement • Business Wire • 03/22/2024 07:00:00 PM
- MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board • Business Wire • 03/21/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:15:28 PM
- MAIA Biotechnology to Participate in the 36th Annual ROTH Conference • Business Wire • 03/07/2024 02:45:00 PM
- MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting • Business Wire • 03/06/2024 04:04:00 PM
- MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients • Business Wire • 03/06/2024 01:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:00:38 PM
- MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders • Business Wire • 03/05/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 10:23:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:17:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/14/2024 10:18:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:15:18 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM